Aimmune Therapeutics, Inc. (AIMT): Price and Financial Metrics

Aimmune Therapeutics, Inc. (AIMT): $34.49

0.10 (-0.29%)

POWR Rating

Component Grades








Add AIMT to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




in industry

AIMT Price/Volume Stats

Current price $34.49 52-week high $37.00
Prev. close $34.59 52-week low $10.09
Day low $34.48 Volume 987,200
Day high $34.56 Avg. volume 1,714,599
50-day MA $25.92 Dividend yield N/A
200-day MA $21.96 Market Cap 2.26B

AIMT Stock Price Chart Interactive Chart >

Aimmune Therapeutics, Inc. (AIMT) Company Bio

Aimmune Therapeutics is a clinical-stage biopharmaceutical company, engages in the development of desensitization treatments for peanut and other food allergies. The company was founded in 2011 and is based in Brisbane, California.

AIMT Latest News Stream

Event/Time News Detail
Loading, please wait...

AIMT Latest Social Stream

Loading social stream, please wait...

View Full AIMT Social Stream

Latest AIMT News From Around the Web

Below are the latest news stories about Aimmune Therapeutics Inc that investors may wish to consider to help them evaluate AIMT as an investment opportunity.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT

NEW YORK , Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City , is investigating Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") ( AIMT ) relating to the sale of the Company to Sociétés des Produits Nestlé, S.A. Under the terms of the agreement, Aimmune shareholders are anticipated to receive $34.50 per share for each share of Aimmune they own. … Full story available on

Benzinga | September 18, 2020

Merger Arbitrage Analysis And Spread Performance - September 13, 2020

This weekly column explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited. We analyze the attractiveness and profitability of each spread going forward and indicate the trading position or action we have...

Mal Spink, CFA on Seeking Alpha | September 14, 2020

Development of Needle Free Alternatives for Treatment of Anaphylaxis Underway as Aquestive Therapeutics Launches Phase 1 Clinical Trial -

DUBLIN--(BUSINESS WIRE) published a new article on the allergy drugs industry "Allergy Drugs" Nestle has agreed to buy Aimmune Therapeutics Inc in a $2.6 billion deal. Nestle has built a large health science business focused on dietary management and the deal will add Aimmunes's Palforzia to its portfolio. Palforzia is the first FDA approved treatment to reduce the frequency and severity of allergic reactions to peanuts in children and teenagers. The drug is derived from

Business Wire | September 11, 2020

Aimmune Therapeutics: A Bargain For A Potential Blockbuster Therapy

Investment Thesis Earlier this year, Aimmune Therapeutics, Inc. (AIMT) unveiled Palforzia, the first and only FDA approved therapy to suppress the effects of peanut allergy. The lockdown measures hindered its market launch, and the company failed to realize sales to arrest the stock’s decline. Despite a rich portfolio of drugs...

Dulan Lokuwithana on Seeking Alpha | September 9, 2020

AIMMUNE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of  Aimmune Therapeutics Inc. - AIMT

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of  Aimmune Therapeutics Inc. (NasdaqGS: AIMT) to Sociétés des Produits Nestlé, S.A. Under the terms of the proposed transaction, shareholders of Aimmune will receive only $34.50 in cash for each share of Aimmune that they own. KSF is seeking to determine whether this consideration and the process that led to i

Business Wire | September 4, 2020

Read More 'AIMT' Stories Here

AIMT Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year 72.45%
2023 N/A
2022 N/A
2021 N/A
2020 0.00%
2019 39.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!